NCT02863796已完成不适用
The Safety and Feasibility of the WhiteSwell System for the Reduction of Interstitial Fluid Overload in Patients With Acutely Decompensated Heart Failure
WhiteSwell, Limited4 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2016年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 4
- 主要终点
- The Rate of adjudicated device- or procedure-related Serious Adverse Events vents
研究概览
简要总结
Early feasibility study to evaluate safety and performance of the WhiteSwell System in the treatment of fluid overload in hospitalized patients with acutely decompensated heart failure.
详细描述
This study will evaluate the safety and feasibility of the WhiteSwell System for the treatment of patients hospitalized with acutely decompensated heart failure. Subjects who have been admitted to the hospital less than 72 hours for ADHF will be evaluated for inclusion into the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Age \>18
- •2. Subject is admitted to the hospital with a primary diagnosis of acute decompensated heart failure (ADHF).
- •3. Subjects receiving IV diuretic for ADHF and demonstrating fluid overload. This includes a minimum of 2 of the following:
- •* peripheral edema ≥ +2 (on a 0 to +3 scale, indicating indentation of skin with mild digital pressure that requires 10 s or more to resolve in any dependent area including extremities or sacral region);
- •* jugular venous distension ≥8 cm H2O
- •* pulmonary edema or pleural effusion on chest radiograph
- •* enlarged liver or ascites;
- •* paroxysmal nocturnal dyspnea or ≥ two-pillow orthopnea;
- •* dyspnea at rest with respiration rate ≥20 per minute
- •4. Renal function parameters: 30\400 pg/ml or NT-pro-BNP\>1,600 pg/ml
- •2. For patients with rate-controlled persistent or permanent AF: BNP\>600 pg/ml or NT-pro-BNP\>2,400 pg/ml
- •6. Subject must be able to be enrolled into the trial ≤ 72 hours of their admission to the hospital
- •7. Subject agrees to comply with all follow-up evaluations
- •8. Subject has provided written informed consent; or if unable to perform informed consent, written informed consent on behalf of the subject has been provided by a legally-authorized representative
排除标准
- •Subjects requiring inotropic therapy, mechanical ventilation, or mechanical circulatory support
- •Subjects developing worsening renal function (creatinine >0.5 mg/dL above baseline) within the time frame from admission to enrollment.
- •Subject has experienced a thromboembolic event (eg, pulmonary embolism (PE), deep vein thrombosis (DVT)) within the previous 6 months
- •Subject has contraindications to systemic anticoagulation
- •Subject with INR >1.8 or on novel anticoagulants (NOACs). Subjects who have taken NOACs may be enrolled if a minimum of 48 hours has passed since their last dose, with the exception of subjects on Dabigatran, who may not be enrolled.
- •Subject has mechanical heart valve.
- •Subject with systolic blood pressure < 90mmHg at time of enrollment
- •Subject has evidence of active infection
- •Subject has anatomical abnormalities and variations, or visualization of the insertion and deployment site does not enable safe venous access and device deployment as assessed by ultrasound
- •Subject vein diameters proximal and distal to the internal jugular/subclavian vein bifurcation in area of device placement less than 13.5mm and/or greater than 205mm.
- •Subject has experienced transient ischemic attack (TIA) events or cerebrovascular events (CVA) at previous 6 months
- •Subject with Acute coronary syndrome (ACS).
- •Subject with severe concomitant disease expected to prolong hospitalization or expected to cause death in ≤ 90 days
- •Subject is pregnant. Pregnancy confirmed by positive urine or serum test, or lactating mothers
结局指标
主要结局
The Rate of adjudicated device- or procedure-related Serious Adverse Events vents
时间窗: 30 days
The rate of adjudicated device- or procedure-related Serious Adverse Events (SAEs). All primary safety endpoints will be reported as-adjudicated by the designated Clinical Events Committee (CEC) during treatment and through the 30-day follow-up period.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
The Safety and Feasibility of the eLym™ SystemDecompensation, Congestive HeartNCT05747196WhiteSwell, Limited70
已完成
不适用
Safety and Feasibility of a Novel Device for Assessing Respiratory Function in ChildrenAsthma in ChildrenNCT04873193ResMed30
已完成
不适用
BlueWind Medical Reprieve System for the Treatment of PNPPeripheral NeuropathyNCT02062398BlueWind Medical13
进行中（未招募）
不适用
Trial for Reliability of Urodynamics SysTemUrologic DiseasesUrodynamicsNCT05694793Bright Uro28
终止
不适用
Safety and Feasibility Evaluation of the Arterica Closure Device designed for the closure of artery access sites following Endovascular proceduresACTRN12620000773932Arterica, Inc.4